Effect of infliximab treatment on qt intervals in patients with ankylosing spondylitis

Journal of Investigative Medicine

Volumn 59, Issue 8, 2011, Pages 1273-1275

  Senel, Soner ^a   Cobankara, Veli ^b   Taskoylu, Ozgur ^b   Guclu, Aydin ^b   Evrengul, Harun ^b   Kaya, Mehmet Gungor ^c  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Ankylosing spondylitis; Cardiovascular involvement; Infliximab; QT dispersion

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MALE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROSPECTIVE STUDY; QT DISPERSION; QT INTERVAL; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 84856720070     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182330720     Document Type: Article

References (22)

1. Khan MA. Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, et al, eds. Rheumatology. 3rd ed. London, UK: Mosby; 2003:1161-1181.
2. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;6:557-563.
3. O'Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis. 1992;51:705-706.
4. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med. 1997;127:621-629.
5. Brunner F, Kunz A, Weber U, et al. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol. 2006;25:24-29.
6. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91;988-998. (Pubitemid 35416635)
7. Okin PM, Devereux RB, Howard BV, et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. Circulation. 2000;101:61-66. (Pubitemid 30039077)
8. Costantini O, Drabek C, Rosenbaum DS. ReviewVCan sudden cardiac death be predicted from the Twave of the ECG? A critical examination of Twave alternans and QT interval dispersion. Journal of Pacing, Arrhythmias and Cardiac Electrophysiology (PACE). 2000;16(23):1407-1416.
9. Crow RS, Hannan PJ, Folsom AR. Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up. Circulation. 2003;108:1985-1989. (Pubitemid 37296543)
10. Dekker JM, Crow RS, Hannan PJ, et alARIC Study. Heart rateYcorrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol. 2004;43:565-571. (Pubitemid 38229526)
11. Strohmer B, Pichler M, Iglseder B, et al. Relationship of QT interval duration with carotid intima media thickness in a clinically healthy population undergoing cardiovascular risk screening. J Intern Med. 2005;257:238-246. (Pubitemid 40342126)
12. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368. (Pubitemid 14134775)
13. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-2291.
14. Akkoc Y, Karatepe AG, Akar S, et al. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int. 2005;25:280-284. (Pubitemid 40767833)
15. Kaya MG, Baykan A, Dogan A, et al. Intermediate-term effects of transcatheter closure of secundum atrial septal defect on cardiac remodeling in children and adults. Pediatr Cardiol. 2010;31:474-482.
16. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34:585-592. (Pubitemid 39643120)
17. Lazzerini PE, Acampa M, Hammoud M, et al. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol. 2008;35(10):1958-1965. Epub 2008 Aug.
18. Curione M, Aratari A, Amato S, et al. A study on QT interval in patients affected with inflammatory bowel disease without cardiac involvement. Intern Emerg Med. 2010;5(4):307-310. E-pub April 22, 2010.
19. Mehta SJ, Berger J, Tan KH. Peripheral arterial thrombosis following administration of infliximab for Crohn disease. Grand Rounds. 2010;10:78-81.
20. Sote Y, Green S, Maddison P. Complete heart block after infliximab therapy. Rheumatology (Oxford). 2008;47:227-228. (Pubitemid 351168243)
21. Panteris V, Perdiou A, Tsirimpis V, et al. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease. World J Gastroenterol. 2006;12:6235-6238. (Pubitemid 44688181)
22. Niemann JT, Youngquist S, Rosborough JP, et al. Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model. Crit Care Med. 2010;38:1162-1167.